AR112328A1 - Composiciones y métodos para tratamiento de cáncer usando bifidobacterium animalis ssp. lactis - Google Patents

Composiciones y métodos para tratamiento de cáncer usando bifidobacterium animalis ssp. lactis

Info

Publication number
AR112328A1
AR112328A1 ARP180101879A AR112328A1 AR 112328 A1 AR112328 A1 AR 112328A1 AR P180101879 A ARP180101879 A AR P180101879A AR 112328 A1 AR112328 A1 AR 112328A1
Authority
AR
Argentina
Prior art keywords
lactis
bifidobacterium animalis
animalis ssp
strain
subject
Prior art date
Application number
Other languages
English (en)
Spanish (es)
Original Assignee
Evelo Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63036353&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR112328(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Evelo Biosciences Inc filed Critical Evelo Biosciences Inc
Publication of AR112328A1 publication Critical patent/AR112328A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ARP180101879 2017-07-05 2018-07-05 Composiciones y métodos para tratamiento de cáncer usando bifidobacterium animalis ssp. lactis AR112328A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762528669P 2017-07-05 2017-07-05

Publications (1)

Publication Number Publication Date
AR112328A1 true AR112328A1 (es) 2019-10-16

Family

ID=63036353

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP180101879 AR112328A1 (es) 2017-07-05 2018-07-05 Composiciones y métodos para tratamiento de cáncer usando bifidobacterium animalis ssp. lactis

Country Status (12)

Country Link
US (3) US10792314B2 (enExample)
EP (1) EP3648780A1 (enExample)
JP (1) JP7254786B2 (enExample)
KR (1) KR102563191B1 (enExample)
CN (1) CN111356464A (enExample)
AR (1) AR112328A1 (enExample)
AU (1) AU2018298087A1 (enExample)
BR (1) BR112019028301A2 (enExample)
CA (1) CA3068757A1 (enExample)
MA (1) MA51770A (enExample)
TW (1) TW201906620A (enExample)
WO (1) WO2019010255A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
WO2016196605A1 (en) * 2015-06-01 2016-12-08 The University Of Chicago Treatment of cancer by manipulation of commensal microflora
MA41010B1 (fr) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
IL265109B2 (en) 2016-09-13 2024-05-01 Allergan Inc Stabilized non-protein clostridial toxin compositions
JP7212945B2 (ja) 2017-05-22 2023-01-26 フォーディー ファーマ リサーチ リミテッド 細菌株を含む組成物
TW201907931A (zh) 2017-05-24 2019-03-01 英商4D製藥研究有限公司 包含細菌菌株之組合物
WO2018229188A1 (en) 2017-06-14 2018-12-20 4D Pharma Research Limited Compositions comprising bacterial strains
MD3804737T2 (ro) 2017-06-14 2022-10-31 4D Pharma Res Limited Compoziții care conțin tulpini bacteriene
CN115813955A (zh) 2017-06-14 2023-03-21 4D制药研究有限公司 包含细菌菌株的组合物
TW201906620A (zh) 2017-07-05 2019-02-16 美商艾弗洛生物科技股份有限公司 使用動物雙岐桿菌乳亞種 (bifidobacterium animalis ssp. lactis) 治療癌症之組合物及方法
EP3768285A1 (en) 2018-03-19 2021-01-27 4D Pharma Research Limited Compositions comprising bacterial strains
CA3106139A1 (en) 2018-07-16 2020-01-23 4D Pharma Research Limited Compositions comprising bacterial strains
MA54161A (fr) 2018-12-12 2022-03-23 4D Pharma Res Ltd Compositions comprenant des souches bactériennes parabacteroides pour le traitement du cancer
WO2020252144A1 (en) * 2019-06-11 2020-12-17 Evelo Biosciences, Inc. Secreted microbial extracellular vesicles
WO2021022110A1 (en) 2019-08-01 2021-02-04 Evelo Biosciences, Inc. Inducing immune effects using bacteria of the genus bifidobacterium
KR102357904B1 (ko) * 2019-10-29 2022-02-04 경희대학교 산학협력단 항암용 금 나노입자
CN112618577B (zh) * 2020-12-15 2023-07-25 深圳君拓生物科技有限公司 动物双歧杆菌在提高肿瘤免疫治疗应答中的作用
US20240124905A1 (en) * 2021-01-26 2024-04-18 Cb Therapeutics, Inc. Recombinant Polyprenol Diphosphate Synthases
TW202304415A (zh) * 2021-04-08 2023-02-01 美商艾弗洛生物科技股份有限公司 含有細菌的藥物製劑
CN113368259B (zh) * 2021-06-22 2022-07-22 海南大学 一种基于修饰细菌加载纳米药物的方法及其复合物和在治疗结肠癌中的应用
US20230096810A1 (en) * 2021-09-24 2023-03-30 Johnson & Johnson Consumer Inc. Dosage forms for the delivery of a probiotic
CN114028432A (zh) * 2021-11-05 2022-02-11 上海市第十人民医院 双歧杆菌提升铂类化疗药物敏感性的药物新用途
CN115363094A (zh) * 2021-11-30 2022-11-22 内蒙古伊利实业集团股份有限公司 乳双歧杆菌bl-99在预防和/或改善胃炎中的应用
CN114480229B (zh) * 2022-04-15 2022-08-09 微康益生菌(苏州)股份有限公司 一种动物双歧杆菌乳亚种菌株wkb148及其产品与应用
CN115216423B (zh) * 2022-06-15 2023-04-25 南昌大学 一种动物双歧杆菌sf及其在医药和食品中的应用
WO2025071560A1 (en) * 2023-09-28 2025-04-03 Rutgers, The State University Of New Jersey Methods of diagnosing b cell malignancies, detecting b cell malignancy relapse, and treating thereof
CN117417866B (zh) * 2023-10-27 2026-02-27 江南大学 一种产胆盐水解酶的动物双歧杆菌及其在新生儿黄疸中的应用
CN117327632B (zh) * 2023-12-01 2024-02-13 四川厌氧生物科技有限责任公司 一种动物双歧杆菌及其应用
CN121046519B (zh) * 2025-11-05 2026-03-20 中国食品发酵工业研究院有限公司 动物双歧杆菌乳亚种bl-99的活菌定量检测方法及其引物、探针、试剂盒与应用

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ID29150A (id) 1999-01-15 2001-08-02 Entpr Ireland Cs Penggunaan lactobacillus salivarius
US20030092163A1 (en) 2001-07-26 2003-05-15 Collins John Kevin Probiotic bifidobacterium strains
GB0307026D0 (en) 2003-03-27 2003-04-30 Rowett Res Inst Bacterial supplement
EP1481681A1 (en) 2003-05-30 2004-12-01 Claudio De Simone Lactic acid bacteria combination and compositions thereof
JP4683881B2 (ja) 2003-08-27 2011-05-18 有限会社アーク技研 抗腫瘍活性剤
GB0323039D0 (en) 2003-10-01 2003-11-05 Danisco Method
EP1714660A1 (en) 2005-04-21 2006-10-25 N.V. Nutricia Uronic acid and probiotics
WO2007140613A1 (en) 2006-06-06 2007-12-13 Mcgill University Fermented milk product and use thereof
US20080069861A1 (en) 2006-09-19 2008-03-20 National Starch And Chemical Investment Holding Corporation Probiotic/Non-Probiotic Combinations
EP1920782A1 (en) 2006-11-10 2008-05-14 Glycotope Gmbh Carboyhdrate specific cellular immunity inducing microorganisms and fractions thereof
RU2473681C2 (ru) 2007-03-28 2013-01-27 Элиментари Хелт Лимитед ПРОБИОТИЧЕСКИЙ ШТАММ Bifidobacterium longum, КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ ТАКОЙ ШТАММ, И ЕГО ПРИМЕНЕНИЕ
RU2466185C2 (ru) 2007-03-28 2012-11-10 Элиментари Хелт Лимитед ПРОБИОТИЧЕСКИЙ ШТАММ Bifidobacterium longum, ПРОБИОТИЧЕСКАЯ КОМПОЗИЦИЯ И ПРИМЕНЕНИЯ ШТАММА Bifidobacterium longum
EP1997907A1 (en) 2007-06-01 2008-12-03 Friesland Brands B.V. Bifidobacteria
HUP0700552A2 (en) 2007-08-27 2009-03-30 Janos Dr Feher Method and composition inhibiting inflammation
ES2431572T3 (es) 2007-10-20 2013-11-27 Université de Liège Especies bifidobacterianas
WO2009149149A1 (en) 2008-06-04 2009-12-10 Trustees Of Dartmouth College Prevention or treatment of immune-relevant disease by modification of microfloral populations
RU2546251C2 (ru) 2009-11-11 2015-04-10 Алиментари Хелс Лимитед Пробиотический штамм бифидобактерий
WO2012142605A1 (en) 2011-04-15 2012-10-18 Samaritan Health Services Rapid recolonization deployment agent
AU2014239883B2 (en) * 2013-03-14 2019-01-17 Therabiome, Llc Targeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents
EP3033091B1 (en) 2013-08-16 2022-09-07 Versitech Limited Probiotic composition and use thereof in the prevention and treatment of hepatocellular carcinoma
WO2015038731A1 (en) 2013-09-12 2015-03-19 The Johns Hopkins University Biofilm formation to define risk for colon cancer
EP2876167A1 (en) 2013-11-21 2015-05-27 Institut Gustave Roussy Microbiota composition, as a marker of responsiveness to chemotherapy, and use of microbial modulators (pre-,pro- or synbiotics) for improving the efficacy of a cancer treatment
CA2946463A1 (en) 2014-05-05 2015-11-12 Giovanni Mogna Therapy for use in the treatment of tumors, acquired immunodeficiency syndrome and leukemias by dual immune biostimulation
CN104224851B (zh) 2014-08-15 2018-08-24 中国农业大学 动物双歧杆菌乳酸亚种CGMCC No.9273的应用
MA41020A (fr) 2014-11-25 2017-10-03 Evelo Biosciences Inc Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome
KR102735818B1 (ko) 2015-01-23 2024-11-28 템플 유니버시티-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 암 예방에서 단쇄 지방산의 용도
WO2016172658A2 (en) 2015-04-23 2016-10-27 Kaleido Biosciences, Inc. Microbiome regulators and related uses thereof
EP3964234A1 (en) 2015-04-23 2022-03-09 Kaleido Biosciences, Inc. Glycan therapeutics and methods of treatment
WO2016196605A1 (en) 2015-06-01 2016-12-08 The University Of Chicago Treatment of cancer by manipulation of commensal microflora
MD3650033T2 (ro) 2015-06-15 2022-08-31 4D Pharma Res Ltd Compoziții conţinând tulpini bacteriene
CN106110322A (zh) * 2016-07-29 2016-11-16 安徽瀚海博兴生物技术有限公司 一种药物组合物及其在制备治疗癌症药物中的应用
TW201906620A (zh) 2017-07-05 2019-02-16 美商艾弗洛生物科技股份有限公司 使用動物雙岐桿菌乳亞種 (bifidobacterium animalis ssp. lactis) 治療癌症之組合物及方法

Also Published As

Publication number Publication date
JP7254786B2 (ja) 2023-04-10
CA3068757A1 (en) 2019-01-10
US20190192585A1 (en) 2019-06-27
BR112019028301A2 (pt) 2020-07-14
US10576111B2 (en) 2020-03-03
KR20200024911A (ko) 2020-03-09
US20190224253A1 (en) 2019-07-25
MA51770A (fr) 2020-05-13
US20210093680A1 (en) 2021-04-01
TW201906620A (zh) 2019-02-16
AU2018298087A1 (en) 2020-01-23
CN111356464A (zh) 2020-06-30
JP2020526581A (ja) 2020-08-31
KR102563191B1 (ko) 2023-08-02
WO2019010255A1 (en) 2019-01-10
EP3648780A1 (en) 2020-05-13
US10792314B2 (en) 2020-10-06

Similar Documents

Publication Publication Date Title
ES2561253T3 (es) Bacterias probióticas que tienen actividad antioxidante y uso de las mismas
MX2019008196A (es) Microorganismos programados para producir moduladores inmunes y productos terapéuticos anti-cáncer en células tumorales.
AR111207A1 (es) Anticuerpos anti-lag3
AR110684A1 (es) Composiciones que comprenden cepas bacterianas y método de tratamiento
EP4578507A3 (en) Compositions and methods for t cell engineering
MX2021010273A (es) Bacterias inmunoestimuladoras modificadas para colonizar tumores, celulas inmunitarias residentes de tumor y el microentorno tumoral.
WO2018170338A3 (en) High affinity mage-a1-specific tcrs and uses thereof
MX2021002415A (es) Celulas madre hematopoyeticas modificadas geneticamente y usos de las mismas.
PH12021552476A1 (en) Compositions and methods for preparing t cell compositions and uses thereof
WO2019033043A3 (en) Anti-cd8 antibodies and uses thereof
BR112016024352A2 (pt) ?cepa de listeria recombinante, listeria recombinante, composição farmacêutica, e, métodos de induzir uma resposta imune contra um tumor ou um câncer em um indivíduo humano e de listeria?
WO2017123675A8 (en) Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells
EA201490512A1 (ru) Композиции, содержащие культивируемую в анаэробных условиях микробиоту кишечника человека
MX2022003005A (es) Composiciones y metodos de anticuerpos anti-cd39.
MX2022007775A (es) Composición para usarse en terapia de microbiota.
AR112166A1 (es) Composiciones terapéuticas y métodos para el tratamiento de hepatitis b
AR107475A1 (es) Cepas fúngicas solubilizantes de fosfato
BR112017021700A2 (pt) composições terapêuticas e métodos de uso para o tratamento do câncer
NZ713423A (en) Bacteriophage therapy
EP4253419A3 (en) A vaccine in combination with an immune checkpoint inhibitor for use in treating cancer
RU2015105738A (ru) Непатогенный штамм f18 е. coli и его применение
BR112017018703A2 (pt) peptídeo derivado de gpc3, composição farmacêutica para tratamento ou prevenção de câncer usando o mesmo, indutor de imunidade, e método para produzir células de apresentação de antígeno
MX2020002585A (es) Inhibidor de hdac combinado con un modulador del punto de control inmunitario para la terapia contra el cancer.
EA202191728A1 (ru) Комбинированная терапия arm и естественными клетками-киллерами
BR112017024065A2 (pt) método para tratar insuficiência cardíaca avançada em um indivíduo humano

Legal Events

Date Code Title Description
FB Suspension of granting procedure